Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients

AIDS

Volumn 21, Issue 2, 2007, Pages 179-185

  Naeger, Lisa K ^a   Struble, Kimberly A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Enfurvirtide; HIV protease inhibitor; Resistance; Tipranavir; Virologic response

Indexed keywords

AMINO ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ENFUVIRTIDE; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; PYRIDINES; PYRONES; TREATMENT OUTCOME;

EID: 33845925741     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280119213     Document Type: Article

References (14)

1. Food and Drug Administration. Guidance for Industry: Role of HIV Drug Resistance Testing in Antiretroviral Development. Made available 26 November 2004. Available at http://www.fda.gov/cder/guidance/5879dft.htm. Accessed: 23 October 2006.
2. Poppe SM, Slade DE, Chong K, Hinshaw R, Pagano P, Markowitz M, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997; 41:1058-1063.
3. Larder B, Hertogs K, Bloor S, van den Eynde Ch, DeCian W, Wang Y, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14:1943-1948.
4. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, et al. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from subjects with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000; 44:1328-1332.
5. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 2005; 68:27-35.
6. Food and Drug Administration Clinical and Statistical Reviews available at http://www.fda.gov/cder/foi/nda/2005/21814_000_AptivusTOC.htm Made available 22 June 2005. Accessed: 23 October 2006.
7. Food and Drug Administration Microbiology Reviews available at http://www.fda.gov/cder/foi/nda/2005/21814_000_AptivusTOC.htm Made available 22 June 2005. Accessed: 23 October 2006.
8. Hall D, McCallister S, Neubacher D, Kraft M and Mayers DL. Characterization of treatment-emergent resistance mutations in two phase II studies of tipranavir. XII International HIV Drug Resistance Workshop, June 2003, Cabo del Sol, Los Cabos, Mexico. Antiviral Therapy 8:S16.
9. Hivinsite.ucsf.edu 2006.
10. Johnson V, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes D, Pillay D, et al. Update of drug resistance mutations in HIV-1:2005. Topics in HIV Medicine 2005; 13:51-57.
11. Hivdb.stanford.edu 1998-2006.
12. Kohlbrenner VM, Hall DB, Schapiro J, Baxter J, Boucher CA, Frank M, et al. Development of a tipranavir mutation score: analysis of protease mutations associated with phenotypic drug susceptibility and antiviral response in Phase II clinical trials. XIII International HIV Drug Resistance Workshop, June 2004, Tenerife, Canary Islands, Spain. Antiviral Therapy 9 (suppl):S143 [Abstract 129].
13. Valdez H, Hall DB, Kohlbrenner VM, Boucher CA, Schapiro J, Baxter J, et al. Non-response to tipranavir is associated with pre-treatment resistance characterized by tipranavir phenotype or geneoytpic tipranavir score. XIV International HIV Drug Resistance Workshop, June 2005, Quebec City, Canada. Antiviral Therapy 10 (suppl 1):S29 [Abstract 27].
14. Aptivus (Tipranavir) package insert. Boëhringer Ingelheim, Ridgefield, Connecticut, USA.